



Living Cell Technologies Ltd

Suite 2.11 / 737 Burwood Rd

Hawthorn VIC 3122

ABN: 14 104 028 042

COMPANY ANNOUNCEMENT

LCT to present at Royal Society of New Zealand meeting

15 August 2006, Auckland, New Zealand:

Living Cell Technologies Ltd (ASX:LCT) today announced Medical Director Prof Bob Elliott will speak at the Royal Society of New Zealand (RSNZ) meeting this week on the 200th anniversary of the discovery of the subantarctic Auckland Islands.

At the forthcoming RSNZ meeting on August 18, Prof Elliott, has been asked to speak on the unique biology of LCT's Biocert[®] pigs and how they now play a crucial role in fighting human diseases such as type 1 diabetes and neurological disorders.

"LCT has established a unique herd of medical-grade pigs that we've demonstrated to be an ideal source of cells for treating diseases such as diabetes," said Prof Elliott.

"Located on the Auckland Islands between the south island of New Zealand and Antarctica for centuries without human contact, the isolation of the LCT Biocert[®] pigs has kept them free of infections common in other herds," said Prof Elliott.

The LCT pig herd in New Zealand are direct descendants of pigs left on the islands almost two hundred years ago by whalers as a source of food for their returning sailors.

Since 1999, LCT has selectively bred these pigs in isolation to meet international regulatory guidelines which specify the cleanliness of pig tissue for treating human disease.

"From our pre-IND meeting with the US FDA in late 2005 and feedback from LCT presentations at international diabetes and transplant meetings, including the recent meeting of the International Xenotransplantation Association in Boston, we are confident that we have an ideal source of pig tissue," said Mr David Collinson, LCT CEO.

"Other companies and scientists around the world have also realised that a secure supply of pig cells is essential as they are now required to use the same high health status pig cells in pre-clinical studies as they do in clinical trials and the resulting clinical product. LCT's Biocert[®] pigs have become very important to these researchers," said Mr Collinson.

There is strong and growing international interest from cell transplant, biomaterial and medical device companies in gaining access to LCT's herd.

The pigs must be bred and raised in isolation from all other animals in a pathogen free environment, protected from possible infections from birds, rodents and insects and be raised on feed that is free of mammalian components for at least three generations. The herds are carefully tested every step of the way.

Insulin, clotting factors, collagen and heart valves from pigs have been used safely in human medicine for many years.

LCT has filed a patent for a method of breeding and selecting high health status pigs for medical use to the approved FDA standard.

LCT currently has two pig facilities in New Zealand with plans for an additional SPF unit in development. Discussions are underway for the establishment of a US facility.

Further information:		
Prof Bob Elliott Medical Director Tel: +64 9 270 7943 Mob: +64 272 924 177	David Collinson Chief Executive Officer Tel: +64 9 276 2690 Mobile: +61 402 716 984	Paris Brooke General Manager – Australia Tel: +61 3 9813 5501 Mobile: + 61 407 715 574

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies Ltd (ASX: LCT) develop live cell therapy products to treat life threatening human diseases. The ASX listed, vertically integrated company operates globally through offices in New Zealand, Australia and the United States. LCT focuses on developing treatments where healthy living cells are injected into patients to replace or repair damaged tissue, without requiring the use of toxic drugs to prevent rejection. The company's product portfolio focuses on treatments for people with Huntington's disease, insulin-dependent diabetes and haemophilia.